Adoptive immunotherapy using immune effector cells has revolutionized cancer treatments with approval of two autologous chimeric antigen receptor(CAR)T cell therapies by the US FDA.Clinical trials using natural killer...Adoptive immunotherapy using immune effector cells has revolutionized cancer treatments with approval of two autologous chimeric antigen receptor(CAR)T cell therapies by the US FDA.Clinical trials using natural killer(NK)cell-based adoptive immunotherapy have been shown to be safe and effective for treatment of multiple malignancies,especially acute myelogenous leukemia.However,most of these trails use primary NK cells isolated from peripheral or cord blood which can have donor-dependent variability and can be challenging to genetic engineer to improve antitumor functions,limiting the widespread use of this promising new therapy.NK cells can now be routinely produced from human pluripotent stem cells,both human embryonic stem cells(hESCs)and induced pluripotent stem cells(iPSCs).These pluripotent stem cells are homogenous,easy to genetically modify on a clonal level and can be used as unlimited source of NK cells,making them ideal population to develop standardized,off-the-shelf adoptive NK cell therapy products.In this review,we discuss recent advances of obtaining and expanding hESC and iPSC-derived NK cells and novel genetic engineering strategies that are being applied to improve their antitumor functions.展开更多
Cellular immunotherapy harnesses the body’’s own immune system to fight cancer by using engineered T cells,macrophages,or natural killer(NK)cells.Compared to chimeric antigen receptor T(CAR-T)cells that are commonly...Cellular immunotherapy harnesses the body’’s own immune system to fight cancer by using engineered T cells,macrophages,or natural killer(NK)cells.Compared to chimeric antigen receptor T(CAR-T)cells that are commonly used to treat hematological malignancies,CAR-NK cells have shown remarkable therapeutic effectiveness while exhibiting enhanced safety,reduced risk of graft-versus-host disease,fewer side effects,and amplified antitumor efficacy.Preclinical trials have unveiled the high potential of adoptive CAR-NK cell therapy to curtail or even eliminate both hematological malignancies and solid tumors in animal models.We brought forth herein the design principle of CAR-NK cells,highlighted the latest progress in the preclinical testing and clinical trials of CAR-NK cells,briefly delved into discussed major roadblocks in CAR-NK therapy,and discussed potential solutions to surmount these challenges.Given the accelerated progress in both basic and translational studies on immune cell engineering,CAR-NK cell therapy promises to become a serious contender and important addition to the next-generation cell-based immunotherapy.展开更多
目的观察乳腺肿瘤细胞膜MHCⅠ链相关分子A(MHC class I chain-related gene A,MICA)及血清中可溶性MICA表达,探讨MICA在NK细胞杀伤乳腺癌中的作用。方法流式细胞术检测膜型MICA(mMICA)及NK细胞表面NKG2D表达,观察膜型MICA、可溶性MICA(s...目的观察乳腺肿瘤细胞膜MHCⅠ链相关分子A(MHC class I chain-related gene A,MICA)及血清中可溶性MICA表达,探讨MICA在NK细胞杀伤乳腺癌中的作用。方法流式细胞术检测膜型MICA(mMICA)及NK细胞表面NKG2D表达,观察膜型MICA、可溶性MICA(sMICA)对NKG2D表达的影响;免疫组织化学检测膜型MICA及可溶性MICA的表达及分布;抗体封闭法观察膜型MICA与NKG2D相互作用。结果乳腺细胞膜型MICA在正常组织不表达,在良性肿瘤表达量为(38.5±7.5)%,恶性肿瘤表达量为(53.2±5.6)%。可溶性MICA含量在健康成年人为阴性,在乳腺良性肿瘤患者血清中含量(76.8±22.3)pg/mL,在恶性肿瘤患者中含量(205.36±71.27)pg/mL。经NKG2D或MICA抗体封闭后,NK细胞的杀瘤活性显著减弱。含可溶性MICA的血清可明显下调NKG2D的表达。结论大部分乳腺肿瘤细胞膜都有MICA的表达,可作为乳腺肿瘤相关性抗原。膜型MICA与NKG2D的相互识别在介导NK细胞抗乳腺癌中起重要作用,而可溶性MICA通过下调NKG2D表达介导肿瘤免疫逃逸。展开更多
目的:探讨MHC-Ⅰ类链相关分子A(MHC class I chain-related molecule A,MICA)多态性与乳腺癌细胞对NK细胞杀伤敏感性的关系。方法:测序分析乳腺癌细胞系MCF-7、MDA-MB-231、MDA-MB-435S和SK-BR-3的MICA等位基因,用Western blotting和流...目的:探讨MHC-Ⅰ类链相关分子A(MHC class I chain-related molecule A,MICA)多态性与乳腺癌细胞对NK细胞杀伤敏感性的关系。方法:测序分析乳腺癌细胞系MCF-7、MDA-MB-231、MDA-MB-435S和SK-BR-3的MICA等位基因,用Western blotting和流式细胞术检测MICA重组表达载体转染293T细胞(分别命名为p MCFA5.1、p MCFA4、p231A5R、p231A9和p435A5P)MICA蛋白的表达水平,用LDH法检测NK细胞对转染MICA的293T细胞的杀伤活性,酶联免疫斑点法检测NK细胞穿孔素、颗粒酶B分泌水平。结果:MCF-7细胞表达MICA*008/A5.1和MICA*001/A4,MDA-MB-231和SK-BR-3细胞均表达MICA*019/A5和MICA*002/A9,MDA-MB-435S细胞表达MICA*010/A5。转染MICA后,p MCFA5.1组293T细胞MICA蛋白的表达水平最低(P<0.05),p435A5P组次之(P<0.05),p MCFA4组、p231A5R组和p231A9组表达水平较高(均P<0.05)。NK细胞对转染MICA的293T细胞杀伤活性及穿孔素、颗粒酶B分泌:p435A5P组对NK细胞杀伤的敏感性最低(P<0.05),穿孔素、颗粒酶B分泌水平最低(均P<0.05);p MCFA5.1、p MCFA4、p231A5R和p231A9各组之间比较差异无统计学意义(P>0.05)。结论:MICA基因多态性与乳腺癌细胞对NK细胞杀伤的敏感性密切相关。展开更多
文摘Adoptive immunotherapy using immune effector cells has revolutionized cancer treatments with approval of two autologous chimeric antigen receptor(CAR)T cell therapies by the US FDA.Clinical trials using natural killer(NK)cell-based adoptive immunotherapy have been shown to be safe and effective for treatment of multiple malignancies,especially acute myelogenous leukemia.However,most of these trails use primary NK cells isolated from peripheral or cord blood which can have donor-dependent variability and can be challenging to genetic engineer to improve antitumor functions,limiting the widespread use of this promising new therapy.NK cells can now be routinely produced from human pluripotent stem cells,both human embryonic stem cells(hESCs)and induced pluripotent stem cells(iPSCs).These pluripotent stem cells are homogenous,easy to genetically modify on a clonal level and can be used as unlimited source of NK cells,making them ideal population to develop standardized,off-the-shelf adoptive NK cell therapy products.In this review,we discuss recent advances of obtaining and expanding hESC and iPSC-derived NK cells and novel genetic engineering strategies that are being applied to improve their antitumor functions.
基金Cancer Prevention and Research Institute of Texas(Grant/Award Number:RP210070)National Cancer Institute(Grant/Award Number:R01CA232017)Welch Foundation(Grant/Award Number:BE-1913-20220331)。
文摘Cellular immunotherapy harnesses the body’’s own immune system to fight cancer by using engineered T cells,macrophages,or natural killer(NK)cells.Compared to chimeric antigen receptor T(CAR-T)cells that are commonly used to treat hematological malignancies,CAR-NK cells have shown remarkable therapeutic effectiveness while exhibiting enhanced safety,reduced risk of graft-versus-host disease,fewer side effects,and amplified antitumor efficacy.Preclinical trials have unveiled the high potential of adoptive CAR-NK cell therapy to curtail or even eliminate both hematological malignancies and solid tumors in animal models.We brought forth herein the design principle of CAR-NK cells,highlighted the latest progress in the preclinical testing and clinical trials of CAR-NK cells,briefly delved into discussed major roadblocks in CAR-NK therapy,and discussed potential solutions to surmount these challenges.Given the accelerated progress in both basic and translational studies on immune cell engineering,CAR-NK cell therapy promises to become a serious contender and important addition to the next-generation cell-based immunotherapy.
文摘目的观察乳腺肿瘤细胞膜MHCⅠ链相关分子A(MHC class I chain-related gene A,MICA)及血清中可溶性MICA表达,探讨MICA在NK细胞杀伤乳腺癌中的作用。方法流式细胞术检测膜型MICA(mMICA)及NK细胞表面NKG2D表达,观察膜型MICA、可溶性MICA(sMICA)对NKG2D表达的影响;免疫组织化学检测膜型MICA及可溶性MICA的表达及分布;抗体封闭法观察膜型MICA与NKG2D相互作用。结果乳腺细胞膜型MICA在正常组织不表达,在良性肿瘤表达量为(38.5±7.5)%,恶性肿瘤表达量为(53.2±5.6)%。可溶性MICA含量在健康成年人为阴性,在乳腺良性肿瘤患者血清中含量(76.8±22.3)pg/mL,在恶性肿瘤患者中含量(205.36±71.27)pg/mL。经NKG2D或MICA抗体封闭后,NK细胞的杀瘤活性显著减弱。含可溶性MICA的血清可明显下调NKG2D的表达。结论大部分乳腺肿瘤细胞膜都有MICA的表达,可作为乳腺肿瘤相关性抗原。膜型MICA与NKG2D的相互识别在介导NK细胞抗乳腺癌中起重要作用,而可溶性MICA通过下调NKG2D表达介导肿瘤免疫逃逸。